Ovidrel Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

Summary of safety profile: In comparative trials with different doses of Ovidrel, OHSS was found to be associated with Ovidrel in a dose-related fashion: OHSS was observed in approximately 4% of patients treated with Ovidrel. Severe OHSS was reported in less than 0.5% patients (see Precautions).
List of adverse reactions: The following definitions apply to the frequency terminology used hereafter: very common (≥1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Immune system disorders: Very rare: Mild to severe hypersensitivity reactions including rash, anaphylactic reactions and shock.
Nervous system disorders: Common: Headache.
Vascular disorders: Very rare: Thromboembolism.
Gastrointestinal disorders: Common: Abdominal pain, abdominal distention, nausea, vomiting. Uncommon: Abdominal discomfort, diarrhoea.
Reproductive system and breast disorders: Common: Mild or moderate OHSS.
Uncommon: Severe OHSS.
General disorders and administration site conditions: Common: Injection site reactions.

View ADR Monitoring Form

choriogonadotropin alfa

Manufacturer:

Merck

Distributor:

Apex Pharma Marketing